April 28 (Reuters) - Life science real estate investment

trust Alexandria Real Estate Equities ( ARE ) reduced its

full-year forecast for adjusted funds from operations (FFO) on

Monday due to anticipated lower leasing activity.

The Pasadena, California-based REIT operates and develops

life science laboratories, offices and technology campuses

across North America.

Alexandria now expects its full-year 2025 adjusted FFO to be

between $9.16 and $9.36 per share, down from its previous

forecast range of $9.23 to $9.43 per share, expecting lower

leasing activity during the year.

Analysts, on average, expect the company to report an FFO of

$9.27 per share, according to data compiled by LSEG.

With clients including Bristol Myers Squibb ( BMY ), Moderna ( MRNA )

and Eli Lilly ( LLY ), the company faces further

uncertainty because its pharma clients risk higher costs due to

U.S. President Donald Trump's plans to impose tariffs on

imported pharmaceutical products.

Shares of the company were down close to 1% in aftermarket

trading.

Occupancy of Alexandria's operating properties in North

America, as of March 31, stood at 91.7%.

The company reported first-quarter FFO, a key performance

measure for REITs, of $2.30 per share, compared with $2.25 per

share a year ago.

Total revenue for the quarter was $758.2 million, down from

$769.1 million from a year earlier.

The company reported a net loss of $11.6 million, or 7 cents

per share, for the quarter ended March 31, compared with a

profit of $166.9 million, or 97 cents per share, from the same

period last year.